The Liver Meeting 2024

Children with autoimmune liver disease and their caregivers face numerous challenges, but their health-related ...

MAY 27, 2025

In this second part of a two-part series, Ashwani Singal, MD, MS, discusses abstracts on treatment of severe ...

MAY 22, 2025

Elafibranor and seladelpar, both recently approved by the FDA for treatment of PBC, showed prolonged efficacy and ...

MAY 20, 2025

The newly approved drug seladelpar was found to be safe and effective in treating patients with both PBC and ...

MAY 15, 2025

The results of several studies presented at The Liver Meeting 2024 suggest there is a robust treatment pipeline for ...

MAY 14, 2025

Ashwani Singal, MD, MS, discusses abstracts on managing variceal bleeding, hepatocellular carcinoma and more.

APRIL 14, 2025

Liver transplant may be a poor indicator of disease progression in progressive familial intrahepatic cholestasis ...

APRIL 10, 2025

A patient- and caregiver-targeted app reduced avoidable hospital readmissions in cirrhosis patients compared with ...

MARCH 18, 2025

Patients with MASH fibrosis taking resmetirom who lost at least 5% of their body weight had a higher rate of ...

MARCH 7, 2025

From groundbreaking clinical trials to comprehensive educational opportunities at major conferences, APPs ...

FEBRUARY 20, 2025

Bariatric surgery and weight loss medications both have been used to reduce mortality risk in patients with liver ...

FEBRUARY 17, 2025

Elafibranor is predicted to increase transplant-free survival and reduce mortality over 15 years in patients with ...

FEBRUARY 13, 2025